ストックスクリーナーアプリを入手
27.18
0.15%
-0.04
前日終値:
$27.22
開ける：
$27.25
24時間の取引高:
891.37K
Relative Volume:
0.62
時価総額：
$1.58B
収益：
$32.87M
当期純損益:
$674.31M
株価収益率:
2.3926
EPS:
11.36
ネットキャッシュフロー:
$-330.11M
1週間 パフォーマンス:
-3.00%
1か月 パフォーマンス:
+0.74%
6か月 パフォーマンス:
-23.11%
1年 パフォーマンス:
-14.64%
1日の値動き範囲:
$26.56
$27.25
1週間の範囲:
$26.56
$28.00
52週間の値動き範囲:
$22.24
$46.00
Agios Pharmaceuticals Inc Stock (AGIO) Company Profile
名前
Agios Pharmaceuticals Inc
セクター
電話
617-649-8600
住所
88 SIDNEY STREET, CAMBRIDGE, MA
AGIO を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AGIO
Agios Pharmaceuticals Inc
|
27.18 | 1.59B | 32.87M | 674.31M | -330.11M | 11.36 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Agios Pharmaceuticals Inc Stock (AGIO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-11-24 | 開始されました | Truist | Buy |
| 2025-11-20 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2025-11-19 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-24 | 開始されました | H.C. Wainwright | Buy |
| 2024-10-16 | 開始されました | Scotiabank | Sector Outperform |
| 2024-10-10 | 再開されました | Raymond James | Outperform |
| 2024-09-27 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2024-02-08 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-02-03 | 開始されました | Piper Sandler | Overweight |
| 2022-11-17 | アップグレード | Goldman | Sell → Neutral |
| 2022-07-27 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2021-12-03 | 開始されました | BofA Securities | Buy |
| 2021-07-30 | ダウングレード | Goldman | Neutral → Sell |
| 2021-07-01 | 開始されました | Raymond James | Mkt Perform |
| 2021-06-10 | 開始されました | H.C. Wainwright | Buy |
| 2021-03-01 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2021-03-01 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2021-02-26 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2020-10-22 | アップグレード | Barclays | Equal Weight → Overweight |
| 2020-03-04 | 開始されました | Barclays | Equal Weight |
| 2019-11-26 | 開始されました | Cantor Fitzgerald | Overweight |
| 2019-09-23 | アップグレード | Guggenheim | Neutral → Buy |
| 2019-05-23 | 再開されました | Goldman | Neutral |
| 2019-02-15 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2018-09-25 | 開始されました | Leerink Partners | Mkt Perform |
| 2018-05-23 | 開始されました | Citigroup | Buy |
| 2018-04-11 | 繰り返されました | Credit Suisse | Outperform |
| 2018-02-15 | 繰り返されました | Needham | Buy |
| 2018-02-15 | 繰り返されました | SunTrust | Buy |
| 2017-09-15 | 開始されました | RBC Capital Mkts | Outperform |
| 2017-08-10 | 繰り返されました | Needham | Buy |
| 2017-08-08 | 繰り返されました | SunTrust | Buy |
| 2017-08-02 | アップグレード | Leerink Partners | Mkt Perform → Outperform |
| 2017-06-26 | ダウングレード | Janney | Buy → Neutral |
| 2017-01-17 | アップグレード | Oppenheimer | Perform → Outperform |
| 2016-10-24 | 開始されました | Needham | Buy |
| 2016-06-13 | アップグレード | JP Morgan | Neutral → Overweight |
| 2016-05-18 | 繰り返されました | SunTrust | Buy |
すべてを表示
Agios Pharmaceuticals Inc (AGIO) 最新ニュース
Insider Selling: Agios Pharmaceuticals (NASDAQ:AGIO) Insider Sells 2,932 Shares of Stock - MarketBeat
Agios Pharmaceuticals (NASDAQ:AGIO) CFO Sells $79,427.88 in Stock - MarketBeat
Agios Pharmaceuticals (NASDAQ:AGIO) CEO Brian Goff Sells 18,703 Shares - MarketBeat
Agios Pharmaceuticals CEO Goff sells $506,663 in stock - Investing.com
Jones Cecilia, Agios Pharmaceuticals CFO, sells $79k in stock By Investing.com - Investing.com UK
Agios Pharma shares jump 16% as US FDA expands approval for blood disorder drug - MSN
Momentum Indicator Shows Bearish Divergence in Sylvan Plyboard India LimitedRisk-Reward Ratio Analysis & Stay Ahead With Daily Market Discussions - earlytimes.in
How Agios Pharmaceuticals Inc. stock valuations compare to rivalsStock Correlation Metrics & Free Superior Profit Margins - bollywoodhelpline.com
Agios Pharma jumps 15% as FDA expands use of anaemia drug mitapivat - MSN
Geopolitics Watch: Is Agios Pharmaceuticals Inc 8AP stock attractive post correctionLayoff News & Low Risk Entry Point Tips - moha.gov.vn
FDA approves Agios’ AQVESME (mitapivat) for the treatment of anemia in adults - MSN
Agios Pharmaceuticals (NASDAQ:AGIO) Shares Down 5.3%Should You Sell? - MarketBeat
Capital One Financial To Rally More Than 24%? Here Are Top Analyst Forecasts For Friday - Benzinga
AGIO: Analyst Andrew Berens Raises Agios Pharmaceuticals Price T - GuruFocus
Agios Pharmaceuticals (AGIO) Surges 18.6%: Is This an Indication of Further Gains? - Yahoo Finance
BofA Securities raises Agios Pharma stock price target on FDA approval - Investing.com India
Here’s why Agios stock (AGIO) is suddenly on the rise today - MSN
Agios (AGIO) Gets 18.6% Boost from Aqvesme OK - Finviz
B of A Securities Maintains Agios Pharmaceuticals (AGIO) Buy Recommendation - MSN
Agios Pharmaceuticals price target raised to $34 from $32 at BofA - Yahoo Finance
Agios Stock (+19%): AQVESME Thalassemia Approval Ignites Re-Rate - Trefis
Agios Pharma shares jump as US FDA expands approval for blood disorder drug - wibqam.com
Why Agios Pharmaceuticals (AGIO) Is Up 14.6% After First-in-Class Thalassemia Drug AQVESME Wins FDA Approval - Sahm
Agios Pharma stock price target raised to $62 from $48 at H.C. Wainwright - Investing.com India
Truist Financial Forecasts Strong Price Appreciation for Agios Pharmaceuticals (NASDAQ:AGIO) Stock - MarketBeat
Agios Pharma Stock: A Buy After FDA Approves Aqvesme (NASDAQ:AGIO) - Seeking Alpha
Here's Why Shares in Agios Pharmaceuticals Popped Today - AOL.com
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Here's Why Shares in Agios Pharmaceuticals Popped Today - The Motley Fool
Agios Pharmaceuticals, Inc. (AGIO) Discusses FDA Approval of AQVESME for Anemia in Alpha and Beta ThalassemiaSlideshow (NASDAQ:AGIO) 2025-12-24 - Seeking Alpha
First oral anemia treatment across thalassaemia types approved in USA - The Pharma Letter
AGIO's Mitapivat Gets FDA Nod for Thalassemia Indication with REMS in Label - Eastern Progress
Agios Pharma shares jump as US FDA expands approval for its blood disorder drug - Yahoo Finance
Agios Pharmaceuticals (NASDAQ:AGIO) Shares Gap Up on Analyst Upgrade - MarketBeat
The $1.7 Billion Pivot: Agios Pharmaceuticals (AGIO) and the New Frontier of Oral Thalassemia Therapy - FinancialContent
AGIO (Agios Pharmaceuticals) EV-to-OCF : -1.89 (As of Dec. 24, 2025) - GuruFocus
Agios (AGIO) Surges 12% Following FDA Approval of New Thalassemi - GuruFocus
Agios Shares Rise After FDA Approves Aqvesme to Treat Anemia in Thalassemia Patients - marketscreener.com
Why Did AGIO Stock Surge 14% Today? - Stocktwits
Agios Pharmaceuticals stock soars after FDA approves AQVESME for thalassemia - Investing.com Canada
Transcript : Agios Pharmaceuticals, Inc.Special Call - marketscreener.com
Bank of America Issues Positive Forecast for Agios Pharmaceuticals (NASDAQ:AGIO) Stock Price - MarketBeat
Agios Pharma shares jump as US FDA expands approval for its blood disorder drug By Reuters - Investing.com
FDA Approves Agios Drug For Thalassemia-Associated AnemiaAgios Pharmaceuticals (NASDAQ:AGIO) - Benzinga
Agios Gets FDA Approval for Aqvesme to Treat Anemia in Thalassemia Patients - marketscreener.com
Assenagon Asset Management S.A. Purchases New Position in Agios Pharmaceuticals, Inc. $AGIO - MarketBeat
Agios Pharmaceuticals secures FDA approval for thalassemia treatment - Investing.com
Agios Pharmaceuticals Inc (AGIO) 財務データ
収益
当期純利益
現金流量
EPS
Agios Pharmaceuticals Inc (AGIO) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Burns James William | Chief Legal Officer |
Dec 30 '25 |
Sale |
27.09 |
2,932 |
79,428 |
31,718 |
| Goff Brian | Chief Executive Officer |
Dec 30 '25 |
Option Exercise |
0.00 |
38,278 |
0 |
149,333 |
| Goff Brian | Chief Executive Officer |
Dec 30 '25 |
Sale |
27.09 |
18,703 |
506,664 |
136,583 |
| Gheuens Sarah | Chief Medical Officer |
Dec 30 '25 |
Option Exercise |
0.00 |
6,000 |
0 |
67,727 |
| Gheuens Sarah | Chief Medical Officer |
Dec 30 '25 |
Sale |
27.09 |
2,932 |
79,428 |
64,795 |
| Milanova Tsveta | Chief Commercial Officer |
Dec 30 '25 |
Option Exercise |
0.00 |
6,000 |
0 |
32,122 |
| Milanova Tsveta | Chief Commercial Officer |
Dec 30 '25 |
Sale |
27.09 |
2,932 |
79,428 |
29,190 |
| Jones Cecilia | Chief Financial Officer |
Dec 30 '25 |
Option Exercise |
0.00 |
6,000 |
0 |
40,326 |
| Jones Cecilia | Chief Financial Officer |
Dec 30 '25 |
Sale |
27.09 |
2,932 |
79,428 |
37,394 |
0.57%
大文字化:
|
ボリューム (24 時間):